Remission of the clinical signs of atopic dermatitis in dogs after cessation of treatment with cyclosporin A or methylprednisolone.
Seventy-eight dogs with atopic dermatitis were treated for four months with either cyclosporin A or methylprednisolone. During the two months after the treatment ceased, 87 per cent of the dogs treated with methylprednisolone relapsed after a mean period of 27.9 days, whereas only 62 per cent of the dogs treated with cyclosporin A relapsed after a mean period of 40.7 days (P < .0.001). The clinical condition of the dogs was evaluated either when they relapsed, or two months after the treatment ceased if they had not relapsed. Both the skin lesions and pruritus increased significantly more markedly in the dogs treated with methylprednisolone than in those treated with cyclosporin A. At the end of the study the skin lesions were markedly less severe than before the therapy; in the dogs in both groups that did not relapse, the lesion score was improved by 77 per cent two months after the treatment had stopped, and in the dogs that did relapse the lesion scores had improved by 45 per cent and 35 per cent in the dogs treated with cyclosporin A and methylprednisolone, respectively. Pruritus remained well controlled in the dogs that did not relapse, but increased to baseline levels or close to baseline in the dogs that relapsed.
Steffan
J
J
Novartis Animal Health, CH-4002 Basel, Switzerland.
Horn
J
J
Gruet
P
P
Strehlau
G
G
Fondati
A
A
Ferrer
L
L
Noli
C
C
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004311:Double-Blind Method; D005500:Follow-Up Studies; D008775:Methylprednisolone / Q000627:therapeutic use*; D011537:Pruritus / Q000473:pathology / Q000662:veterinary; D012008:Recurrence; D012307:Risk Factors; D012720:Severity of Illness Index; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D016572:Cyclosporine; D008775:Methylprednisolone